25 August 2025
: Case report 
Rapid Progression of Primary Hepatic Neuroendocrine Carcinoma: A Case Report Demonstrating Drastic Oncological Behavior
Challenging differential diagnosis, Diagnostic / therapeutic accidents, Rare disease, Adverse events of drug therapy
Rina Kobayashi BF 1, Tomohide Hori
ABCDEF 1*, Makoto Yamawaki CDF 2, Shigeki Nakayama DF 1, Satoru Umegae DF 1, Takao Iwanaga DF 1, Ryutaro Nishikawa D 1, Takahiro Shimoyama DF 1, Sakurako Suzuki F 1, Shinichiro Atsumi CDF 3, Hiroshi Hasegawa F 2, Shigehito Nakashima DF 2, Kunihiro Higuchi F 2, Kentaro Onishi F 2, Ryotaro Sakaguchi F 2, Shoichi Morita F 2, Haruka Miyao F 2, Saki Aota F 2, Hikaru Ohtani F 1, Takayuki Yamamoto ADF 1
DOI: 10.12659/AJCR.948500
Am J Case Rep 2025; 26:e948500
Figure 3 MRI findings 13 days after the initial diagnosisThe hepatic tumor had enlarged to 55 mm (yellow arrows), with tumor thromboses clearly observed in the right HV (A–C, blue arrows) and the anterior branch of the PV (A–C, purple arrows). The tumor appeared hypointense on T1-weighted imaging (A) and hyperintense on T2-weighted imaging (B). Contrast-enhanced T1-weighted imaging did not show any enhancement in the early phase (C). Gadoxetic acid-enhanced MRI at 0.5 (D), 1.5 (E), 3.0 (F), and 4.0 (G) minutes after injection did not reveal early wash-in or wash-out in the hepatic tumor. HV – hepatic vein; MRI – magnetic resonance imaging; PV – portal vein.